Scientific publications
When Cancer Vaccines Go Viral
Aug 15, 2019
| Magazine: Clinical Cancer Research
David Repáraz, Diana Llopiz, Pablo Sarobe
Abstract
Induction of antitumor responses by vaccines requires strong immunogens. Heterologous viral prime/boost immunization with the BN-CV301 vaccine promotes activation of immune responses that provide a clinical benefit to patients with cancer. This viral platform may be used to harbor different antigens and prime tumor immunity potentially useful for combinatorial strategies.
CITATION Clin Cancer Res. 2019 Aug 15;25(16):4871-4873. https://doi.org/10.1158/1078-0432.ccr-19-1652https://doi.org/10.1158/1078-0432.ccr-19-1652. Epub 2019 Jun 21.
Our authors
David Repáraz Pernaut
Predoctoral
Immunology and Immunotherapy Research Program
Dr.
Diana Llópiz Khatchikian
Research Associate
Immunology and Immunotherapy Research Program
Researcher | Principal Investigator
Vaccine Development Research Group